{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:02:51Z","timestamp":1794974571926,"version":"4.9.1"},"reference-count":42,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Status epilepticus (SE) is a serious neurological disease that manifests as prolonged\nseizures that last more than 5 minutes and between such episodes, patients do not regain consciousness.\nIt can result in cognitive defects, brain damage, or even death. It is commonly known that\none of the causes can be an inflammatory process, but here we will focus on inflammation as a result\nof new onset refractory status epilepticus and, related to this, new promising forms of SE treatment.\nParticular emphasis has been focused on new-onset refractory status epilepticus (NORSE).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Based on public research databases, drugs with anti-inflammatory activity \u2013 commonly used\nin different spheres of medicine \u2013 have been reviewed as potentially treating status epilepticus.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>There is seizable clinical research suggesting that drugs that decrease inflammatory processes\nmight be effective in terminating status epilepticus.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>There is growing evidence showing that adding anti-inflammatory drugs to basic antiepileptic\ntreatment enhances the efficiency of the therapeutic process, with special potential in NORSE\ncases.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x21666221117152249","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T05:59:17Z","timestamp":1668751157000},"page":"708-714","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Inflammation as Treatment Target for Status Epilepticus"],"prefix":"10.2174","volume":"21","author":[{"given":"Konrad","family":"Rejdak","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of Lublin, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Pikulicka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Lublin, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Piekarska","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Lublin, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Pacek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Lublin, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"P\u0142achta","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Lublin, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/WCO.0000000000000307","volume":"29","author":"Trinka E.","year":"2016","unstructured":"Trinka E.; Brigo F.; Shorvon S.; Recent advances in status epilepticus. Curr Opin Neurol 2016,29(2),189-198","journal-title":"Curr Opin Neurol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1586\/14737175.2015.1079130","volume":"15","author":"Vezzani A.","year":"2015","unstructured":"Vezzani A.; Dingledine R.; Rossetti A.O.; Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Rev Neurother 2015,15(9),1081-1092","journal-title":"Expert Rev Neurother"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/00004691-199512040-00003","volume":"12","author":"DeLorenzo R.J.","year":"1995","unstructured":"DeLorenzo R.J.; Pellock J.M.; Towne A.R.; Boggs J.G.; Epidemiology of status epilepticus. J Clin Neurophysiol 1995,12(4),316-325","journal-title":"J Clin Neurophysiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1212\/WNL.50.3.735","volume":"50","author":"Hesdorffer D.C.","year":"1998","unstructured":"Hesdorffer D.C.; Logroscino G.; Cascino G.; Annegers J.F.; Hauser W.A.; Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology 1998,50(3),735-741","journal-title":"Neurology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1046\/j.1528-1157.2001.01101.x","volume":"42","author":"Knake S.","year":"2001","unstructured":"Knake S.; Rosenow F.; Vescovi M.; Oertel W.H.; Mueller H.H.; Wirbatz A.; Katsarou N.; Hamer H.M.; Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001,42(6),714-718","journal-title":"Epilepsia"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(06)69043-0","volume":"368","author":"Chin R.F.M.","year":"2006","unstructured":"Chin R.F.M.; Neville B.G.R.; Peckham C.; Bedford H.; Wade A.; Scott R.C.; Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet 2006,368(9531),222-229","journal-title":"Lancet"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(99)00583-8","volume":"353","author":"Jallon P.","year":"1999","unstructured":"Jallon P.; Coeytaux A.; Galobardes B.; Morabia A.; Incidence and case-fatality rate of status epilepticus in the Canton of Geneva. Lancet 1999,353(9163),1496","journal-title":"Lancet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1212\/WNL.46.4.1029","volume":"46","author":"DeLorenzo R.J.","year":"1996","unstructured":"DeLorenzo R.J.; Hauser W.A.; Towne A.R.; Boggs J.G.; Pellock J.M.; Penberthy L.; Garnett L.; Fortner C.A.; Ko D.; A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996,46(4),1029-1035","journal-title":"Neurology"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1001\/archneur.59.2.205","volume":"59","author":"Mayer S.A.","year":"2002","unstructured":"Mayer S.A.; Claassen J.; Lokin J.; Mendelsohn F.; Dennis L.J.; Fitzsimmons B.F.; Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002,59(2),205-210","journal-title":"Arch Neurol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/epi.12271","volume":"54","author":"Janigro D.","year":"2013","unstructured":"Janigro D.; Iffland P.H.; Marchi N.; Granata T.; A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia 2013,54(Suppl. 6),30-32","journal-title":"Epilepsia"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3389\/fnmol.2018.00341","volume":"11","author":"Wang M.","year":"2018","unstructured":"Wang M.; Chen Y.; Inflammation: A network in the pathogenesis of status epilepticus. Front Mol Neurosci 2018,11,341","journal-title":"Front Mol Neurosci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1097\/WNR.0000000000000878","volume":"28","author":"Wang Y.","year":"2017","unstructured":"Wang Y.; Liu X.; Wang Y.; Chen J.; Han T.; Su L.; Zang K.; Attenuation of pentylenetrazole-induced acute status epilepticus in rats by adenosine involves inhibition of the mammalian target of rapamycin pathway. Neuroreport 2017,28(15),1016-1021","journal-title":"Neuroreport"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.phrs.2016.03.039","volume":"107","author":"Citraro R.","year":"2016","unstructured":"Citraro R.; Leo A.; Constanti A.; Russo E.; De Sarro G.; mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res 2016,107,333-343","journal-title":"Pharmacol Res"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107742","volume":"167","author":"Terrone G.","year":"2020","unstructured":"Terrone G.; Balosso S.; Pauletti A.; Ravizza T.; Vezzani A.; Inflammation and reactive oxygen species as disease modifiers in epilepsy. Neuropharmacology 2020,167","journal-title":"Neuropharmacology"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.yebeh.2015.04.047","volume":"49","author":"Gorter J.A.","year":"2015","unstructured":"Gorter J.A.; van Vliet E.A.; Aronica E.; Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis. Epilepsy Behav 2015,49,13-16","journal-title":"Epilepsy Behav"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1523\/JNEUROSCI.2751-17.2018","volume":"38","author":"Rempe R.G.","year":"2018","unstructured":"Rempe R.G.; Hartz A.M.S.; Soldner E.L.B.; Sokola B.S.; Alluri S.R.; Abner E.L.; Kryscio R.J.; Pekcec A.; Schlichtiger J.; Bauer B.; Matrix metalloproteinase-mediated blood-brain barrier dysfunction in epilepsy. J Neurosci 2018,38(18),4301-4315","journal-title":"J Neurosci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.expneurol.2004.02.010","volume":"187","author":"Kasselman L.J.","year":"2004","unstructured":"Kasselman L.J.; Ransohoff R.M.; Cai N.; Croll S.D.; Cai N.; Zhang Q.; Martin F.J.; Wei T.; Kintner J.; Murphy A.J.; Yancopoulos G.D.; Wiegand S.J.; Vascular endothelial growth factor (VEGF)-mediated inflammation precedes angiogenesis in adult rat brain. Exp Neurol 2004,187,388-402","journal-title":"Exp Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/00005072-199906000-00006","volume":"58","author":"Proescholdt M.A.","year":"1999","unstructured":"Proescholdt M.A.; Heiss J.D.; Walbridge S.; M\u00fchlhauser J.; Capogrossi M.C.; Oldfield E.H.; Merrill M.J.; Oldfield E.H.; Merrill M.J.; Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol 1999,58(6),613-627","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"11534","DOI":"10.1073\/pnas.190206797","volume":"97","author":"Vezzani A.","year":"2000","unstructured":"Vezzani A.; Moneta D.; Conti M.; Richichi C.; Ravizza T.; De Luigi A.; De Simoni M.G.; Sperk G.; Andell-Jonsson S.; Lundkvist J.; Iverfeldt K.; Bartfai T.; Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci USA 2000,97(21),11534-11539","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1046\/j.1528-1157.43.s.5.14.x","volume":"43","author":"Vezzani A.","year":"2002","unstructured":"Vezzani A.; Moneta D.; Richichi C.; Aliprandi M.; Burrows S.J.; Ravizza T.; Perego C.; De Simoni M.G.; Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. Epilepsia 2002,43(Suppl. 5),30-35","journal-title":"Epilepsia"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/epi.16405","volume":"61","author":"Hanin A.","year":"2020","unstructured":"Hanin A.; Lambrecq V.; Denis J.A.; Imbert-Bismut F.; Rucheton B.; Lamari F.; Bonnefont-Rousselot D.; Demeret S.; Navarro V.; Cerebrospinal fluid and blood biomarkers of status epilepticus. Epilepsia 2020,61(1),6-18","journal-title":"Epilepsia"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13054-015-1072-9","volume":"19","author":"Sutter R.","year":"2015","unstructured":"Sutter R.; Valen\u00e7a M.; Tschudin-Sutter S.; R\u00fcegg S.; Marsch S.; Procalcitonin and mortality in status epilepticus: an observational cohort study. Crit Care 2015,19(1),361","journal-title":"Crit Care"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.seizure.2018.09.018","volume":"68","author":"Sculier C.","year":"2019","unstructured":"Sculier C.; Gaspard N.; New onset refractory status epilepticus (NORSE). Seizure 2019,68,72-78","journal-title":"Seizure"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/WNP.0000000000000761","volume":"37","author":"Alkhachroum A.","year":"2020","unstructured":"Alkhachroum A.; Der-Nigoghossian C.A.; Rubinos C.; Claassen J.; Markers in status epilepticus prognosis. J Clin Neurophysiol 2020,37(5),422-428","journal-title":"J Clin Neurophysiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/dmcn.14553","volume":"62","author":"Specchio N.","year":"2020","unstructured":"Specchio N.; Pietrafusa N.; New\u2010onset refractory status epilepticus and febrile infection\u2010related epilepsy syndrome. Dev Med Child Neurol 2020,62(8),897-905","journal-title":"Dev Med Child Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/ana.25439","volume":"85","author":"Clarkson B.D.S.","year":"2019","unstructured":"Clarkson B.D.S.; LaFrance-Corey R.G.; Kahoud R.J.; Farias-Moeller R.; Payne E.T.; Howe C.L.; Functional deficiency in endogenous interleukin\u20101 receptor antagonist in patients with febrile infection\u2010related epilepsy syndrome. Ann Neurol 2019,85(4),526-537","journal-title":"Ann Neurol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3174\/ajnr.A5929","volume":"40","author":"Strohm T.","year":"2019","unstructured":"Strohm T.; Steriade C.; Wu G.; Hantus S.; Rae-Grant A.; Larvie M.; FDG-PET and MRI in the Evolution of New-Onset Refractory Status Epilepticus. AJNR Am J Neuroradiol 2019,40(2),238-244","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jns.2017.08.021","volume":"381","author":"Nardetto L.","year":"2017","unstructured":"Nardetto L.; Zoccarato M.; Santelli L.; Tiberio I.; Cecchin D.; Giometto B.; 18F-FDG PET\/MRI in cryptogenic new-onset refractory status epilepticus: a potential marker of disease location, activity and prognosis? J Neurol Sci 2017,381,100-102","journal-title":"J Neurol Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbi.2016.12.015","volume":"61","author":"Bertoglio D.","year":"2017","unstructured":"Bertoglio D.; Verhaeghe J.; Santermans E.; Amhaoul H.; Jonckers E.; Wyffels L.; Van Der Linden A.; Hens N.; Staelens S.; Dedeurwaerdere S.; Non-invasive PET imaging of brain inflammation at disease onset predicts spontaneous recurrent seizures and reflects comorbidities. Brain Behav Immun 2017,61,69-79","journal-title":"Brain Behav Immun"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.eplepsyres.2017.09.003","volume":"137","author":"Szklener S.","year":"2017","unstructured":"Szklener S.; Korchut A.; Godek M.; Balicka-Adamik L.; Bielecki D.; Rejdak R.; Rejdak K.; Systemic inflammatory response syndrome in the course of status epilepticus: 7-year, two-center observational study. Epilepsy Res 2017,137,53-55","journal-title":"Epilepsy Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.seizure.2012.12.016","volume":"22","author":"Gall C.R.E.","year":"2013","unstructured":"Gall C.R.E.; Jumma O.; Mohanraj R.; Five cases of new onset refractory status epilepticus (NORSE) syndrome: Outcomes with early immunotherapy. Seizure 2013,22(3),217-220","journal-title":"Seizure"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2324709619848816","author":"Ramos A.B.","year":"2019","unstructured":"Ramos A.B.; Cruz R.A.; Villemarette-Pittman N.R.; Olejniczak P.W.; Mader E.C.; Dexamethasone as abortive treatment for Refractory seizures or status epilepticus in the inpatient setting. J Investig Med High Impact Case Rep 2019,7","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40265-017-0859-1","volume":"78","author":"Holtkamp M.","year":"2018","unstructured":"Holtkamp M.; Pharmacotherapy for refractory and super-refractory status epilepticus in adults. Drugs 2018,78(3),307-326","journal-title":"Drugs"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1212\/CON.0000000000000668","volume":"24","author":"Nelson S.E.","year":"2018","unstructured":"Nelson S.E.; Varelas P.N.; Status epilepticus, refractory status epilepticus, and super-refractory status epilepticus. Continuum (Minneap Minn) 2018,24(6),1683-1707","journal-title":"Continuum (Minneap Minn)"},{"key":"ref=35","first-page":"135","volume":"118","author":"Westbrook C.","year":"2019","unstructured":"Westbrook C.; Subramaniam T.; Seagren R.M.; Tarula E.; Co D.; Furstenberg-Knauff M.; Wallace A.; Hsu D.; Payne E.; Febrile infection-related epilepsy syndrome treated successfully with anakinra in a 21-year-old woman. WMJ 2019,118(3),135-139","journal-title":"WMJ"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.nbd.2013.07.015","volume":"59","author":"Noe F.M.","year":"2013","unstructured":"Noe F.M.; Polascheck N.; Frigerio F.; Bankstahl M.; Ravizza T.; Marchini S.; Beltrame L.; Bander\u00f3 C.R.; L\u00f6scher W.; Vezzani A.; Pharmacological blockade of IL-1\u03b2\/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis 2013,59,183-193","journal-title":"Neurobiol Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.25374","volume":"84","author":"Jun J.S.","year":"2018","unstructured":"Jun J.S.; Lee S.T.; Kim R.; Chu K.; Lee S.K.; Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol 2018,84(6),940-945","journal-title":"Ann Neurol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S1474-4422(10)70310-0","volume":"10","author":"Pitk\u00e4nen A.","year":"2011","unstructured":"Pitk\u00e4nen A.; Lukasiuk K.; Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011,10(2),173-186","journal-title":"Lancet Neurol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s12035-014-8648-2","volume":"50","author":"Ambrogini P.","year":"2014","unstructured":"Ambrogini P.; Minelli A.; Galati C.; Betti M.; Lattanzi D.; Ciffolilli S.; Piroddi M.; Galli F.; Cuppini R.; Post-seizure \u03b1-tocopherol treatment decreases neuroinflammation and neuronal degeneration induced by status epilepticus in rat hippocampus. Mol Neurobiol 2014,50(1),246-256","journal-title":"Mol Neurobiol"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106454","volume":"167","author":"Koh S.","year":"2020","unstructured":"Koh S.; Dupuis N.; Auvin S.; Ketogenic diet and Neuroinflammation. Epilepsy Res 2020,167","journal-title":"Epilepsy Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/j.1528-1167.2011.03250.x","volume":"52","author":"Kramer U.","year":"2011","unstructured":"Kramer U.; Chi C.S.; Lin K.L.; Specchio N.; Sahin M.; Olson H.; Nabbout R.; Kluger G.; Lin J.J.; van Baalen A.; Febrile infection-related epilepsy syndrome (FIRES): Pathogenesis, treatment, and outcome. Epilepsia 2011,52(11),1956-1965","journal-title":"Epilepsia"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13054-017-1645-x","volume":"21","author":"Cruz F.F.","year":"2017","unstructured":"Cruz F.F.; Rocco P.R.M.; Pelosi P.; Anti-inflammatory properties of anesthetic agents. Crit Care 2017,21(1),67","journal-title":"Crit Care"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X21666221117152249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211021\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X21666221117152249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T04:31:00Z","timestamp":1693715460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211021\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x21666221117152249","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}